Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation

Ki vehet részt

• Patients who provide written informed consent form (ICF) to participate in the study
• Male and female
• ≥ 18 years old
• Diagnosis of moderate or severe HS (Hurley stage and IHS4)
• Patient who initiated treatment with secukinumab no longer than 4 weeks prior to written ICF
• Decision for secukinumab prescription was made by the attending physician according to the approved national label during routine clinical practice, regardless of study participation

Ki nem vehet részt

• Patients who received any vaccine within 4 weeks prior to secukinumab initiation
• Any medical or psychological condition that may prevent the study participation, based on practitioners' decision-making
• Known or suspected severe hypersensitivity for secukinumab, formulation excipients, or injection device components (i.e., latex)
• Clinically significant infection exacerbation, including active tuberculosis
• Patients with active inflammatory bowel disease (IBD)
• Age <18 years
• Participation in an ongoing clinical trial
• Pregnancy and breastfeeding